Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganlu Qingwen
- Development stage
- Unknown
- Lead developer
- Yiling Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ganlu Qingwen is a Traditional Chinese Medicine (TCM) granule formulation developed by the Fourth Affiliated Hospital of Xinjiang Medical University (also known as the Affiliated TCM Hospital of Xinjiang Medical University). Originally formulated to treat community-acquired pneumonia (CAP) and acute lung injury (ALI), it gained significant prominence during the COVID-19 pandemic as a regional treatment protocol in Xinjiang, China. The preparation is designed to clear heat, resolve dampness, and detoxify. Pharmacologically, it is reported to reduce systemic inflammation by downregulating pro-inflammatory cytokines such as Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α), thereby mitigating the cytokine storm associated with severe viral pneumonia and lung injury. It is officially approved as a hospital preparation (医院制剂) in the Xinjiang Uygur Autonomous Region.
- Brand names
- Ganlu Qingwen
- Other names
- Ganlu Qingwen GranulesGanlu Qingwen FormulaGanlu Qingwen Keli
02
Targets
NF-κBNLRP3 (Nod-like receptor family pyrin domain-containing protein 3)TNFA (Tumor necrosis factor alpha (soluble))STAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on Ganlu Qingwen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ganlu Qingwen.